Search

NC-6300

NC-6300, also known as K-912, is a novel [epirubicin] drug-conjugated polymeric micelle.

Livmoniplimab

With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)). … Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination

Teprenone

XL999

XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. … XL999 has the potential to prevent tumor growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response.

Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. … In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection[A226853].

GC5107

It is marketed as IVIG-SN.

CCR5 mAb

It was generated by HGS using the Abgenix XenoMouse technology.

YKP-1358

YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.

Viralym-C

It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]

Zibrofusidic acid

Zibrofusidic acid has a monoisotopic molecular weight of 594.26 Da.